Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: ...
3don MSN
Exclusive: NewcelX advances diabetes therapy toward human trials with FDA pre-IND submission
NewcelX Ltd. NCEL, a regenerative medicine company, on Wednesday announced the submission of a Pre-IND briefing package to ...
Newcelx Ltd. has submitted a pre-IND briefing package to the U.S. FDA to support a proposed first-in-human trial of NCEL-101 in combination with tegoprubart, an investigational anti-CD40L monoclonal ...
Newcelx Ltd. has entered into a collaborative research agreement with Eledon Pharmaceuticals Inc. with the aim of advancing its lead program, NCEL-101, for type 1 diabetes. NCEL-101 is designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results